Vericel Corporation last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $85.4 million (+26.5% year over year) and diluted EPS of $0.27. It usually reports 13–37 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 12, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Jan 13, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 13–37 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
85
+26.5%
|
14
+179.1%
|
0.27
+170.0%
|
|
Jul 30, 2026
30 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
77
+22.5%
|
2
+498.9%
|
0.04
+500.0%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
68
+30.1%
|
-6
+44.0%
|
-0.12
+47.8%
|
|
Jan 13, 2026
13 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
93
+23.3%
|
23
+17.3%
|
0.40
+23.3%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
68
+16.6%
|
5
+663.2%
|
0.10
+600.0%
|
|
Jul 31, 2025
31 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
63
+20.1%
|
-1
+88.2%
|
-0.01
+90.0%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
53
+2.6%
|
-11
-191.2%
|
-0.23
-187.5%
|
|
Jan 14, 2025
14 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
75
+16.0%
|
20
+52.4%
|
0.33
+19.9%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VCEL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- MI
- Headquarters
- Burlington, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 887359
- Former names
- AASTROM BIOSCIENCES INC (until Nov 14, 2014)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.